NCKAP1 Rabbit Polyclonal Antibody

CAT#: TA351428

Rabbit Polyclonal Anti-NCKAP1 Antibody

Size: 25 ul 100 ul



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (2)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Transient overexpression lysate of NCK-associated protein 1 (NCKAP1), transcript variant 1
    • 100 ug

CNY 3,080.00

Specifications

Product Data
Applications IHC
Recommend Dilution IHC: 25-100
Positive control: Human brain
Predicted cell location: Cytoplasm
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen Synthetic peptide of human NCKAP1
Formulation pH7.4 PBS, 0.05% NaN3, 40% Glyceroln
Concentration lot specific
Purification Antigen affinity purification
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Gene Name NCK associated protein 1
Background NAP125, also known as NCKAP1 (NCK-associated protein 1), p125Nap1 or membrane-associated protein HEM-2, is a 1,128 amino acid single pass membrane protein that exists as two alternatively spliced isoforms and belongs to the HEM-1/HEM-2 family. While widely expressed, NAP125 is found at highest levels in heart, brain and skeletal muscle where it regulates Rac-dependent actin remodeling as part of a lamellipodial complex with WAVE2, Abi-1 and CYFIP1. NAP125 localizes to the cytoplasmic side of lamellipodium membrane and is encoded by a gene that maps to human chromosome 2q32.1 and mouse chromosome 2 C3. NAP125 expression is markedly reduced in Alzheimer disease (AD)-affected brains, suggesting a possible role in the disease.
Synonyms HEM2; NAP1; NAP125; p125Nap1
Reference Data
Protein Families Druggable Genome
Protein Pathways Regulation of actin cytoskeleton
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...